Agoracom Blog Home

Archive for the ‘GrowPros Cannabis Ventures Inc.’ Category

GrowPros Announces Name Change to Tetra Bio-Pharma Inc., the Closing of A Non-Brokered Private Placement, and Extends Warrants $GCI.ca

Posted by AGORACOM-JC at 8:36 AM on Wednesday, September 28th, 2016

Growpros_hub_large

  • Changed its name to Tetra Bio-Pharma Inc. and has a new stock symbol CSE:TBP effective immediately

OTTAWA, ONTARIO–(Sept. 28, 2016) - GrowPros Cannabis Ventures Inc. (“GrowPros” or “the Company”) (CSE:GCI) announces that the Company has changed its name to Tetra Bio-Pharma Inc. and has a new stock symbol CSE:TBP effective immediately.

Closing of Private Placement

The Company also announces the closing of a non-brokered private placement of 5,000,000 units at a price of $0.05 per unit for aggregate gross proceeds of $250,000. Each unit consists of one common share and one transferable warrant, with a whole warrant entitling the holder to purchase one common share at a price of $0.07 for a period of twenty-four months expiring September 28, 2018.

In connection with the private placement, the Company will pay a cash finder’s fee of $9,200 and will issue 185,600 non-transferable finder’s warrants. Each finder’s warrant entitles the holder to purchase one common share of the Company at a price of $0.07 per share for a period of twenty-four months expiring September 28, 2018.

The securities issued pursuant to the private placement are subject to a four-month hold period from the closing date and subject to all necessary regulatory approvals, including the approval of the Exchange.

Four insiders participated in the private placement by purchasing 1,480,000 units for a total of $74,000.

The proceeds of the private placement will be used to fund general working capital.

Warrants Extended

The Company has extended the 5,013,000 warrants exercisable at $0.15, issued originally on September 29, 2014 which were set to expire on September 29, 2016 and will now be extended until December 30, 2016.

The Company has recently received $50,130 from exercised warrants.

The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

GrowPros Cannabis Ventures Inc.
Ryan Brown
Director of Communications
(613) 421-8402

GrowPros Cannabis Ventures Inc.
Andre Audet
Executive Chairman
(613) 421-8402

GrowPros Cannabis Ventures Inc.
Andre Rancourt
Interim Chief Executive Officer
(613) 421-8402

Medical Marijuana Seems To Reduce Deaths From Pharmaceuticals $MCOA.us $GCI.ca

Posted by AGORACOM-JC at 4:47 PM on Thursday, September 22nd, 2016
  • Columbia University epidemiologist June Kim and her colleagues report that fatally injured drivers are less likely to test positive for opioids in states that allow medical use of marijuana
  • That finding, together with the results of earlier studies, indicates that making marijuana legally available to patients saves lives by reducing their consumption of more dangerous medications.

BY: Jacob Sullum , Contributor

I cover the war on drugs from a conscientious objector’s perspective.

Opinions expressed by Forbes Contributors are their own.

Marijuana jars at the West Coast Collective, a dispensary in Los Angeles (Image: Frederic J. Brown/AFP/Getty Images)

Insys Therapeutics, the Arizona-based pharmaceutical company that recently became the biggest financial supporter of the campaign against marijuana legalization in that state, makes an oral spray that delivers the opioid painkiller fentanyl and plans to market another one that contains dronabinol, a synthetic version of THC. Insys says it gave $500,000 to the main group opposing Arizona’s legalization initiative because the measure “fails to protect the safety of Arizona’s citizens, and particularly its children.” But one needn’t be terribly cynical to surmise that Insys also worries about the impact that legalization might have on its bottom line, since marijuana could compete with its products.

A new study suggests Insys has good reason to worry. In an article published last week by the American Journal of Public Health, Columbia University epidemiologist June Kim and her colleagues report that fatally injured drivers are less likely to test positive for opioids in states that allow medical use of marijuana. That finding, together with the results of earlier studies, indicates that making marijuana legally available to patients saves lives by reducing their consumption of more dangerous medications.

Kim et al. collected data from the Fatality Analysis Reporting System (FARS) for 1999 through 2013, focusing on 18 states that drug-tested at least 80% of drivers who died in crashes. They found that drivers between the ages of 21 and 40 were half as likely to test positive for opioids in states that had implemented medical marijuana laws (MMLs) as in states that had not.

“Among 21-to-40-year-old deceased drivers, crashing in states with an operational MML was associated with lower odds of testing positive for opioids than crashing in MML states before these laws were operational,” the researchers write. “Although we found a significant association only among drivers aged 21 to 40 years, the age specificity of this finding coheres with what we know about MMLs: a minimum age requirement restricts access to medical marijuana for most patients younger than 21 years, and most surveyed medical marijuana patients are younger than 45 years.”

The fact that a driver tested positive for opioids does not necessarily mean the painkillers he took contributed to the crash, so it is not safe to draw any conclusions about medical marijuana’s impact on traffic safety from this study. But the FARS data are an indirect way of measuring the extent of opioid consumption in a given state. Kim et al. note that “severe or chronic pain is among the most common indications cited by medical marijuana patients.” It therefore makes sense that opioid use would decline (or rise less) in states that recognize cannabis as a medicine.

Source: http://www.forbes.com/sites/jacobsullum/2016/09/22/medical-marijuana-seems-to-reduce-deaths-from-pharmaceuticals/#1a6c82b7396e

PhytoPain Pharma Announces Interview With Radio-Canada Regarding Its Development of a Prescription Marijuana Drug $GCI.ca

Posted by AGORACOM-JC at 9:28 AM on Thursday, September 22nd, 2016

Growpros_hub_large

OTTAWA, ONTARIO–(Sept. 22, 2016) - PhytoPain Pharma (“PPP”), a subsidiary of GrowPros Cannabis Ventures Inc. (“GrowPros” or the “Company” or “GCI“) (CSE:GCI), a pharmaceutical company focused on developing and commercializing therapeutic cannabis-based products for the treatment of pain and other medical conditions announces that it gave an interview to the journalist Brigitte Bureau of Radio-Canada regarding the development of a prescription marijuana drug. Shareholders can view the interview on CBC’s website at http://ici.radio-canada.ca/regions/ottawa/2016/09/21/008-marijuana-medicinale-legalisation-gouvernement-trudeau.shtml

According to Dr. G. Chamberland, Chief Scientific Officer, “PPP is developing a prescription drug marijuana product for consumption via inhalation “smoking”. As part of its mission of bringing botanical-based therapies to patients with chronic diseases while maintaining the characteristics and properties of natural health products but backed by the scientific research and development of Pharma industry. Over the next years, the corporation is planning to develop the evidence to support the prescription of marijuana by physicians and to seek coverage by provincial and federal insurers.” “By implementing this approach, we believe that PPP is addressing the missing link that has existed for years as the major barrier of access to medical cannabis by both patients and physicians across the globe“, commented Ryan Brown, Vice-President of Business Development and Director of Communications for GCI.

Dr. Chamberland further commented that the company intends on submitting a Clinical Trial Application later this year (pre-CTA submitted in August 2016 as per previous news release) and when authorized by Health Canada would initiate its Phase I trial in humans later this year. “PPP001 is in its early stages of development, but based on published clinical trial data, the company is confident that it can bring this product to the market after completing the studies required by regulatory agencies“, commented Dr. Chamberland.

The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

GrowPros Cannabis Ventures Inc.
Dr. Guy Chamberland
Chief Scientific Officer
(514) 220-9225

GrowPros Cannabis Ventures Inc.
Andre Audet
Executive Chairman
(613) 421-8402

GrowPros Cannabis Ventures Inc.
Ryan Brown
President, GrowPros MMP Inc.
(613) 421-8402

GrowPros Changes Its Name to Tetra Bio-Pharma Inc. and Announces the Results of Its Annual Shareholders Meeting $GCI.ca

Posted by AGORACOM-JC at 4:39 PM on Monday, September 19th, 2016

Growpros_hub_large

  • Selected Tetra Bio-Pharma Inc. as the new name for the Company
  • Company also announces the re-appointment of Mr. André Audet as Director of GrowPros and welcomes three new directors on its Board, Mr. André Rancourt, Mr. Robert Brouillette, and Mr. Benoit Chotard.

OTTAWA, ONTARIO–(Sept. 19, 2016) - GrowPros Cannabis Ventures Inc. (“GrowPros” or “the Company”) (CSE:GCI) is pleased to announce that its shareholders have approved an amendment to the Company’s articles of incorporation in order to change its name. The Board of Directors, at a special meeting following the annual shareholders meeting, has selected Tetra Bio-Pharma Inc. as the new name for the Company.

The Company also announces the re-appointment of Mr. André Audet as Director of GrowPros and welcomes three new directors on its Board, Mr. André Rancourt, Mr. Robert Brouillette, and Mr. Benoit Chotard. (Reference to News Release of August 25, 2016)

The firm of McGovern Hurley Cunningham, LLP, was re-appointed as auditors of the Company.

Shareholders have approved the Board’s request for consolidation of the share capital of the Company on the basis of a consolidation ratio of one (1) post-consolidation share for every three (3) pre-consolidation shares. As previously released the consolidation will only be implemented in the case of a major business development.

Non-Brokered Private Placement

The Company also announces a non-brokered private placement (the “Offering”) comprised of 5,000,000 units at a price of $0.05 per unit for gross proceeds of $250,000. Each unit will consist of one common share and one transferable warrant. Each warrant entitles the holder to purchase one common share at a price of $0.07 for a period of twenty-four months following the closing of the Offering. All securities issued pursuant to the private placement are subject to a four-month hold period from the closing date and are subject to all necessary regulatory approvals.

In connection with the private placement, the Company may pay finder’s fees.

The proceeds of the private placement will be used to fund general working capital.

The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

GrowPros Cannabis Ventures Inc.
Andre Rancourt
Interim Chief Executive Officer
(613) 421-8402

GrowPros Cannabis Ventures Inc.
Andre Audet
Chairman
(613) 421-8402

GrowPros Cannabis Ventures Inc.
Ryan Brown
Grow Pros MMP Inc. President
(613) 421-8402

Fed’s Williams sees ‘unsustainable tension’ on pot-related banking $GCI.ca $MCOA.us

Posted by AGORACOM-JC at 8:44 AM on Wednesday, September 7th, 2016
Leaves of marijuana plants to extract the hemp fiber that is often used in traditional Japanese clothes and accessories, are seen at Japan's largest legal marijuana farm in Kanuma, Tochigi prefecture, Japan July 5, 2016. REUTERS/Issei Kato
Leaves of marijuana plants to extract the hemp fiber that is often used in traditional Japanese clothes and accessories, are seen at Japan’s largest legal marijuana farm in Kanuma, Tochigi prefecture, Japan July 5, 2016. REUTERS/Issei Kato

As more and more states legalize the use of marijuana, which is banned under U.S. federal laws, banks are facing “unsustainable tension” that needs to be resolved by Congress, San Francisco Fed President John Williams said on Tuesday.

“This is a big issue for this country,” Williams said after a speech to The Hayek Group in Reno, Nev., where voters will decide whether to legalize some uses of marijuana this November. Pot-related businesses don’t have access to the same bank-run electronic payment systems that are increasingly making transactions safer for most other U.S. businesses, he said.

Source: http://www.reuters.com/article/us-usa-fed-williams-pot-idUSKCN11D06T

GCI Subsiduary PhytoPain Pharma Announces Submission of Orphan Drug Designation Application for Delta-9-tetrahydrocannibinol and Cannabidiol in the United States $GCI.ca

Posted by AGORACOM-JC at 8:53 AM on Tuesday, September 6th, 2016

Growpros_hub_large

  • Submission to the US Food and Drug Administration (FDA) Office of Orphan Products Development,
  • Two applications for Orphan Drug Designation for delta-9-tetrahydrocannibinol and cannabidiol for the treatment of patients with Complex Regional Pain Syndrome Type 1 (CRPS1) and patients with Central PostStroke Pain (CPSP).

OTTAWA, ONTARIO–(Sept. 6, 2016) - PhytoPain Pharma Inc. (“PhytoPain Pharma” or “PPP“), a subsidiary of GrowPros Cannabis Ventures Inc. (“GrowPros” or the “Company“) (CSE:GCI), today announces the submission to the US Food and Drug Administration (FDA) Office of Orphan Products Development, two applications for Orphan Drug Designation for delta-9-tetrahydrocannibinol and cannabidiol for the treatment of patients with Complex Regional Pain Syndrome Type 1 (CRPS1) and patients with Central PostStroke Pain (CPSP). The decision to proceed with these Orphan Drug Designation submissions is part of PPP’s plan to move forward with the development of a cannabis prescription drug product for the treatment of neuropathic pain associated with CRPS1 and CPSP. If successful, the designation of delta-9-tetrahydrocannibinol and cannabidiol as an Orphan Drug will open the door for many opportunities most notably tax credits on clinical research reduction of the waiting period and reduced registration fees. It also provides PPP with a 7-year period of market exclusivity in the U.S.

Dr. Guy Chamberland, M.Sc., Ph.D., Chief Scientific Officer of PhytoPain Pharma, commented: “Our Orphan Drug Designation submissions, announced today, are part of our corporate strategy to develop and commercialize delta-9-tetrahydrocannibinol and cannabidiol prescription drug products for the management of neuropathic pain associated with cancer, HIV, CPSP, and CRPS1 and uncontrolled pain within the United States.” He continued: “I am also very pleased to report that PPP and its collaborators are on track to finalize the Clinical Trial Application (CTA) and submit the clinical protocol to the US Food & Drug Administration (FDA) for review. PPP is developing these prescription drug products for both the Canadian and USA market and intends on obtaining marketing approval from Health Canada and the US FDA. Our medical research team headed by Apical Science Inc. principals Dr. Randy Ringuette, Ph.D. and Dr. Charles Campbell, Ph.D. has been tasked with finalizing these documents for the regulatory agencies.

“This important step positions PPP at the forefront of North American cannabis based consumer drug product development. PPP intends to engage industry partners operating under Canada’s ACMPR (Access to Cannabis for Medical Purposed Regulation) to participate in various aspects of the development process. Being able to leverage this federally legal infrastructure will allow PPP many benefits not available in other jurisdictions”, commented GrowPros CEO Ryan Brown.

The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Contact Information

  • GrowPros Cannabis Ventures Inc.
    Ryan Brown
    Chief Executive Officer
    (613) 421-8402GrowPros Cannabis Ventures Inc.
    André Audet
    Executive Chairman
    (613) 421-8402

    GrowPros Cannabis Ventures Inc.
    Dr. Guy Chamberland
    Chief Scientific Officer and Regulatory Affairs
    (514) 220-9225

FEATURE: GrowPros (GCI:CSE) Natural Pharmaceuticals Derived From Cannabis and Other Medicinal Plants $GCI.ca

Posted by AGORACOM-JC at 12:08 PM on Monday, August 29th, 2016

Growpros_hub_large

Natural Pharmaceuticals Derived From Cannabis and Other Medicinal Plants

Comprised Of Two Divisions

Pharmaceutical Division – PhytoPain Pharma

  • A new subsidiary created June 2, 2016. 80% Ownership
  • Mission is the development and commercialization of botanical based pharmaceuticals
  • A clinical stage drug development company engaged in the development of medication to alleviate symptoms related to: Pain,
    Insomni, anxiety disorder, in patients suffering from Cancer and othe, chronic and terminal diseases

Dr Guy Chamberland, Chief Scientific Officer and Regulatory Affairs

  • Professor of herbal medicine and clinical research at the École d’Enseignement Supérieur de Naturopathie du Québec.
  • 22 years’ experience in the pharmaceutical and natural product industries includes successful development of intellectual property for several botanical drug products

WHY DOCTORS NEED PHARMA MARIJUANA SOLUTIONS

  • A Physician’s decision to prescribe a new drug or even a natural health product has to be based on Evidence-Based Medicine > A legal, ethical requirement
  • Currently, no body of evidence exists to not support the prescription or recommendation of medical marijuana in any medical condition, including terminal cancer
  • The GrowPros pharmaceutical product development plan would provide the data necessary for physicians to prescribe or recommend our products

PRODUCT PIPELINE

Insomnia Management For Patients With Chronic Pain

  • Licensed a hypnotic drug from Mondias Naturals Inc
  • Management of Insomnia in patients with chronic pain
  • Currently in late stage Phase III clinical testing

PhytoPain To Produce A Combination Product

  • Proprietary combination expected to reach Phase I clinical testing in 2017
  • Will be ready for market in 2017 due to combination with Mondias Naturals product

Pain Management – Inhalation Cannabis Drug Product

  • A prescription drug for management of uncontrolled pain in cancer patients
  • Health Canada will provide guidance during Phase I clinical trial
  • Commencing December 2016. Anticipating 3-5 year product development

A recent discussion with the Quebec College of Physicians confirms that pharmaceutical development of a medical marijuana for inhalation would be well received by the medical community.

OPERATIONS OVERVIEW – MMPR

MMPR Division – Collaboration Agreement

  • March 18, 2016 – Signed agreement with Delta 9 Bio-Tech, a “Licensed Producer”
  • Delta 9 will submit to Health Canada an Amendment to collaborate on GrowPros previous application for facility in Southern Quebec; Amendment submission anticipated by June 30, 2106, Health Canada response anticipated August 30, 2016
  • Key Benefits of Delta 9 Collaboration: Significant process clarity, High probability of success eliminates spec construction risk, Single customer through option to acquire all dried marijuana product for 2 years
  • Key strategic benefit to GrowPros; Controlled production, quality and supply for Pharma Division, Value of license, Wholesale seller vs. retail seller

PhytoPain Pharma Announces Appointments to Its Scientific and Clinical Advisory Board $PPP.ca $GCI.ca

Posted by AGORACOM-JC at 8:45 AM on Friday, August 26th, 2016

Growpros_hub_large

  • Announce the creation of its Scientific and Clinical Advisory Board
  • Board is comprised of experts in clinical research, pain management as well as cancer and neurological product drug development

OTTAWA, ONTARIO–(Aug. 26, 2016) - PhytoPain Pharma Inc. (“PhytoPain Pharma” or “PPP“), a subsidiary of GrowPros Cannabis Ventures Inc. (“GrowPros” or the “Company“) (CSE:GCI), is pleased to announce the creation of its Scientific and Clinical Advisory Board. The board is comprised of experts in clinical research, pain management as well as cancer and neurological product drug development. The Advisory Board will provide strategic guidance on PPP’s clinical development program, clinical trial designs, and pipeline of preclinical and clinical candidates for the treatment of pain, insomnia and other conditions affecting cancer patients. “This team of accomplished scientific and clinical experts will collaborate with us on our goal of bringing these new prescription drug products to patients while addressing the concerns of the medical establishment and regulators,” stated Dr. Chamberland, Chief Scientific Officer and Regulatory Affairs.

The President of the board will report directly to the Board of Directors of GCI. The advisory board is expected to meet before the end of October to review the clinical development plan of PPP’s phase I clinical study of smoked cannabis and the development of future cannabis-based therapeutics. PPP intends on submitting the Clinical Trial Application (CTA) after incorporating the recommendations obtained from its expert advisory panel into the clinical development program. PPP also intends on submitting the clinical protocol to the US Food & Drug Administration (FDA) for review. PPP is developing this prescription drug product for both the Canadian and USA market and intends on obtaining approval from Health Canada and the US FDA.

“We are honored to have these distinguished experts join GCI’s new advisory board,” said Ryan Brown CEO of GCI. “We are enlisting these experts to assist PPP in developing prescription drugs for patients suffering from uncontrolled pain.”

The President of the Advisory Board is Dr. Luc Vachon, Ph.D. Dr. Vachon has more than 25 years of experience in drug development. He has worked in two multinational pharmaceutical organizations, a CRO, and two “biotech” companies. He has held various positions, including Global Product Team Leader, Executive V.-P. of R&D, CEO and president, and has also been teaching in the academia. He is presently active as independent consultant in drug development.

Dr. André Bélanger, MD is a member of the pain clinic at the Hôtel-Dieu de Lévis and at Clinique Médicale Valcartier. He is a recognized medical expert in pain management and provides continuing education on pain management for multiple provincial and national programs.

Dr. Gordon D. Ko MD, CCFP(EM), FCFP, FRCPC www.DrKoPRP.com is a specialist in Physical Medicine and Rehabilitation (Physiatry) with subspecialty in Pain Medicine. He is a former Senior University Associate Professor and current Medical Director, Interventional Physiatry clinics and Adjunct Lecturer at Sunnybrook Health Sciences Centre, University of Toronto and the Canadian Centre for Integrative Medicine (Markham). His expertise with Platelet-rich Plasma (PRP) for Back Pain and Botox injections for Osteoarthritis made headline CTV national news. With over 25 years’ experience in treating Fibromyalgia(FMS) and chronic neuropathic pain (including Cannabinoids, Functional Medicine), he was selected on the Canadian Pain Society committee that developed new guidelines (2012) for FMS management. More recently, he was lead author for a peer-reviewed review paper (J Pain Research 2016) on Medical Cannabis: a Canadian Perspective.

Dr. Pierre Arsenault, Ph.D., M.D., CPI is a family medicine practitioner and pain management expert and is an associate professor of family medicine at Université de Sherbrooke. He has a vast experience in clinical research and is a Clinical Physician Investigator (CPI) at DIEX Research.

The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a license for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Contact Information

GrowPros Cannabis Ventures Inc.
Ryan Brown
Chief Executive Officer
(613) 421-8402

GrowPros Cannabis Ventures Inc.
André Audet
Executive Chairman
(613) 421-8402

GrowPros Cannabis Ventures Inc.
Dr. Guy Chamberland
Chief Scientific Officer and Regulatory Affairs
(514) 220-9225

GrowPros Announces Details of Upcoming Annual Shareholder Meeting $GCI.ca

Posted by AGORACOM-JC at 9:17 AM on Thursday, August 25th, 2016

Growpros_hub_large

  • Company will still operate multiple subsidiaries with distinct focuses on Cannabis production (Grow Pros MMP) Consumer product drug development (Phyto Pain Pharma) and natural health product development (Agro-Tek)
  • Company currently has three projects, being its clinical trials, construction of its medical marijuana facility, and development of its natural health products

OTTAWA, ONTARIO–(Aug. 24, 2016) - GrowPros Cannabis Ventures Inc. (“GrowPros” or “the Company”) (CSE:GCI) announces that, at its Annual and Special Meeting of Shareholders, which will be held on September 19th, 2016,

Name Change

In line with its diversification into pharmaceutical development the Company will be requesting approval from its shareholders to change its name to reflect a more accurate depiction of its vision moving forward.

The Company will still operate multiple subsidiaries with distinct focuses on Cannabis production (Grow Pros MMP) Consumer product drug development (Phyto Pain Pharma) and natural health product development (Agro-Tek).

Preparation for the upcoming year

The board and management of GrowPros anticipates an increase in capital requirements as we execute on major milestones not limited to but including construction of our proposed cannabis production facility, beginning stage 1 of clinical trials of PP001 as well as the acquisition of revenue generating assets in the natural health product distribution sector.

The Company currently has three projects, being its clinical trials, construction of its medical marijuana facility, and development of its natural health products, which all require significant funding for further advancement. With this in mind we will be seeking shareholder approval to consolidate its issued and outstanding common shares on the basis of one (1) post-consolidation common share for every three (3) pre-consolidation common shares. This is a proactive measure that would allow us to implement the consolidation congruently with funding of the Company’s three major projects or other potential transactions and acquisitions management identifies moving forward.

The shareholders will be voting on the appointment of three (3) new directors: Mr. André Rancourt, Mr. Robert Brouillette, and Mr. Benoit Chotard who will be replacing Ms. Valerie Lasher, Mr. Koby Smutylo, and Mr. Ryan Brown.

André Rancourt is highly experienced in management, start-up, and commercial strategies for human products. He is also a consultant on several commercial strategy committees including FIA and IRZC. He has tremendous practical experience that provided him with expertise in many fields ranging from metals to the complex area of human and animal natural health products. Over the last ten years, he worked as a consultant to re-organize the operations of companies on behalf of several venture capital investment funds. He has an important network of contacts in the human and animal commercial market in multiple countries. He studied at the Séminaire Sherbrooke from 1969 to1971 and subsequently the University of Sherbrooke (Physical Education). He also successfully completed training in Marketing WarFare. He is often asked by investors to act as a consultant/guide to Presidents of companies.

Robert Brouillette is a lawyer, civil engineer, patent and trade-mark agent. He obtained his engineering degree at the Université de Sherbrooke and his law degree at the Université Laval. He was admitted to the Ordre des ingénieurs du Québec in 1972 and to the Quebec Bar in 1977. He was then appointed trade-mark agent in 1978 and patent agent in 1980. He started his career at Ogilvy Renault in 1977. In 1992, he founded Brouillette Charpentier Fournier (now BCF). In 2005, he founded Brouillette + Partners, a lawyers, patent and trademark agents firm aiming to help builders of innovative companies. Most of his clients are entrepreneurs and a large number of them operate technology companies. He is now recognized in Canada as an expert in the direct selling field. He is also recognized by The Best Lawyers in Canada as an expert in the Information Technology field, and by an expert in the Intellectual Property field. Mr. Brouillette is a former Chairman of the executive committee of the intellectual property national section of the Canadian Bar Association. He was a member of the Board of Directors of Hydro-Québec between 1998 and 2001, Hydro-Québec Capitech and Hydro-Québec Industech between 2001 and 2007. He also serves on the Board of Directors and is an advisor at Simsmart Technologies Inc., Newtrax Technologies, Kinova, Novidev Santé, Intelia, Crowdco and other technology related companies. He is currently chairman of the Board of Directors of Anges Québec and member of the Board of Directors of Capital Anges Québec. He also served as an «angel investor» in over twenty start-ups. His professional path has not only made him an experienced lawyer, but also an entrepreneurship driven and accessible man.

Benoit Chotard has over 20 years of experience in international corporate finance, management, and public market in British Columbia and Québec. Since December 2013, Mr. Chotard is Managing Partner at Capital Force United, a corporate finance advisory corporation that delivers focused advice and transaction expertise, He also was a Partner at Capital Force from January 2011 to November 2013. Since December 2013, Mr. Chotard has also acted as President & CEO, and Director of Orletto Capital Inc., a company listed on the TSX-V. Since 1989, Mr. Chotard is a member of “Ordre des ingénieurs du Québec”. Since January 2011, Mr. Chotard is a financial advisor for public and private corporations. Between October 2009 and December 2010, he was Vice-president Corporate Development for Pakit Inc. a corporation specialized in sustainable cellulose fiber moulding technology to the packaging industry. Between July 2008 and January 2009, he acted as Senior Vice-president Finance Corporate Development and acting as Chief Financial Officer for CANTRONIC Systems (Canada) Inc., a corporation specialized in infrared thermal imaging and thermal imaging and night vision systems. Also, he was Director of Nouveau Monde Mining Enterprises Inc., a mining exploration corporation, from April 2012 to November 2012. During his career, Mr. Chotard spent eight years as Head of the Technology Investment Group of National Bank Financial Inc. Throughout his career he has been a significant contributor in the form of time, knowledge, and capital to many philanthropic organizations including the United Way of Canada. He obtained a bachelor’s degree in Chemical Engineering in 1989 and a Master in Business Administration degree in 1993, both from the University of Sherbrooke.

The Company wishes to thank Ms. Lasher, Mr. Smutylo, and Mr. Brown for their contribution through the years as directors and wishes them well in all their future endeavors.

In Other News

Mr. André Rancourt will be replacing Mr. Ryan Brown as Interim Chief Executive Officer. Mr. Brown will remain President of the Company and sole officer and director of Grow Pros MMP. The subsidiary tasked with obtaining a license to produce cannabis under the MMPR.

Mr. Brown will be focused on adequately capitalising this subsidiary in a manor non dilutive to GCI and will present options to the board at a subsequent board of directors meeting.

Management has allowed the agreement with the acquisition of the assets of Laboratoires Holizen Inc. (“Holizen”) for $450,000, as announced on June 22, 2016, to expire, in order to utilize those resources to pursue opportunities in the United States.

The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Contact Information

  • GrowPros Cannabis Ventures Inc.
    Ryan Brown
    Chief Executive Officer
    (613) 421-8402

GrowPros Announces the Closing of a Non-Brokered Private Placement $GCI.ca

Posted by AGORACOM-JC at 4:47 PM on Monday, August 15th, 2016

Growpros_hub_large

  • Announced the closing of a non-brokered private placement of 2,160,000 units at a price of $0.05 per unit for aggregate gross proceeds of $108,000
  • Unit consists of one common share and one transferable warrant, with a whole warrant entitling the holder to purchase one common share at a price of $0.07 for a period of twenty-four months expiring August 15, 2018

OTTAWA, ONTARIO–(Aug. 15, 2016) - GrowPros Cannabis Ventures Inc. (“GrowPros” or “the Company”) (CSE:GCI) announces the closing of a non-brokered private placement of 2,160,000 units at a price of $0.05 per unit for aggregate gross proceeds of $108,000. Each unit consists of one common share and one transferable warrant, with a whole warrant entitling the holder to purchase one common share at a price of $0.07 for a period of twenty-four months expiring August 15, 2018.

In connection with the private placement, the Company will pay a cash finder’s fee of $4,250 and will issue 85,000 non-transferable finder’s warrants. Each finder’s warrant entitles the holder to purchase one common share of the Company at a price of $0.07 per share for a period of twenty-four months expiring August 15, 2018.

Two insiders participated in the private placement by purchasing 1,000,000 units for a total of $50,000.

The securities issued pursuant to the private placement are subject to a four-month hold period from the closing date and subject to all necessary regulatory approvals, including the approval of the Exchange.

The proceeds of the private placement will be used to fund general working capital.

The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Ryan Brown
Chief Executive Officer
(613) 421-8402